Literature DB >> 12618259

Safety and acceptability of post-abortal IUD insertion and the importance of counseling.

Ahmed El-Tagy1, Ezzat Sakr, David C Sokal, Adel Hakim Issa.   

Abstract

This nonrandomized observational clinical study evaluated the safety and acceptability of intrauterine device insertion either immediately or 2 weeks after abortion, according to the patient's preference. Participants were 300 women with first-trimester abortions who agreed to immediate or delayed insertion. End points were bleeding patterns, pregnancy, expulsion, perforation, infection and device removal at 2, 6 and 10 weeks after insertion, and acceptance rates before and after counseling procedures were improved. The overall initial acceptance rate was 35.8%, and the actual acceptance rate was 31.7%. After counseling procedures were improved, the initial and actual acceptance rates increased substantially (17.7% vs. 44.3% and 10.2% vs. 42.0%, respectively). Bleeding, expulsion rates and pain did not differ significantly between the immediate and delayed insertion groups after IUD insertion. No pregnancies, perforations or cases of pelvic inflammatory disease were recorded in either group. Immediate post-abortal insertion offers the advantage of being a painless procedure. The quality of counseling is critical to improving acceptance of post-abortion contraception.

Entities:  

Mesh:

Year:  2003        PMID: 12618259     DOI: 10.1016/s0010-7824(02)00518-8

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system.

Authors:  Chandra Kailasam; David Cahill
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

2.  Post abortion family planning counseling as a tool to increase contraception use.

Authors:  Ali Ceylan; Meliksah Ertem; Gunay Saka; Nurten Akdeniz
Journal:  BMC Public Health       Date:  2009-01-15       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.